Medizone International Management
David A. Dodd – Chief Executive Officer & Board Member
David Dodd has successfully led the growth and development of companies within life sciences, establishing leadership positions within targeted markets, developing growing employment opportunities and achieving significant shareholder value. He has more than 35 years of executive experience in the healthcare/life sciences industry, successfully guiding the growth and development of such businesses. In addition, Mr. Dodd has been a highly active member of civic, charitable, industry and economic growth organizations, both within the USA and internationally.
From April 2013 until August 2017, Mr. Dodd served as President, CEO of Aeterna Zentaris Inc. (NASDAQ: “AEZS”; www.aezsinc.com); he also served as Chairman of the Board from May 2014 until May 2016. He joined the Company following a series of disappointing clinical development programs that resulted in a Company stock price decrease in excess of 90%. During Mr. Dodd’s tenure at AEZS, a new, commercial-oriented growth strategy was developed, the Company embarked on a comprehensive restructuring, new corporate governance policies were implemented, including a restructuring of the Board of Directors and the Company focused on rapidly transforming into a growth-oriented, commercially based specialty biopharmaceutical company. As a result, Aeterna Zentaris has it’s first New Drug Application (“NDA”) currently under active review by the FDA, with a PDUFA date of December 30, 2017.
Mr. Dodd has served on a number of public and private company boards with such companies as PNP Therapeutics, Aruna Biomedical and GeoVax, a company developing novel vaccines to prevent diseases such as Zika virus, hemoragghic fevers (Ebola, Marburg, Lassa), HIV/AIDS, as well as immune-therapies for oncology and Hepatitis B. He continues to serve as Chairman of GeoVax.
From October 2006 to April 2009, Mr. Dodd served as Non-executive Chairman of Stem Cell Sciences Plc., based in Cambridge, UK, which developed and commercialized research products and services in support of stem cell biological research and development. A publicly-traded company, dual-listed on the LSE:AIM and ASX exchanges, the business was successfully sold to StemCells, Inc., in April 2009.
Mr. Dodd served as President, Chief Executive Officer and Director of Serologicals Corporation (Nasdaq: SERO) from June 2000 to its acquisition by Millipore Corporation in July 2006. Mr. Dodd led a successful transformation of the business, significantly expanding the operations globally and competitively. During his leadership, Serologicals was developed from a value of $85 million in June 2000 to the $1.5 billion acquisition by Millipore.
Previously, Mr. Dodd served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and Chairman of its subsidiary Unimed Pharmaceuticals, Inc. This operation successfully developed from an annual revenue base in 1995 of $100 million to $500 million in 2000, becoming a leader in its respective therapeutic areas, while enterprise value increased from approximately $100 million to $2 billion.
In addition to his successful leadership service within the for-profit sector, Mr. Dodd has served in ongoing leadership roles in support of growing and developing the not-for-profit sector and the overall healthcare and life sciences industry. His service includes/has included serving on the Board of Directors of the Harvard Business School, Health Industry Alumni Association; on the Board of the Medical University of South Carolina Foundation Horizon Project (Charleston, SC); as an advisor to the South Carolina Research Authority (SCRA); as an advisor to Georgia Research Alliance (GRA); as Chairman, GaBio; Chairman of the Metro Atlanta Biosciences Council; Member of the Advisory Board of the Institute of Bioengineering & Biosciences at GaTech; various advisory roles to the Georgia Research Alliance; various roles within the international BIO (Biotechnology Industry Organization); Chairman, American Foundation for Suicide Prevention; the Carter Center Board of Advisors and, many other roles, both domestic and international, in support of the growth and development of the healthcare/life sciences industry. Mr. Dodd received the prestigious Oglethorpe Sword from the British-American Business Group in recognition of his consistent success in forging business relationships between Georgia and the UK. Also, Mr. Dodd was previously selected by the prestigious MacArthur Foundation to be a member of a select 10-person, internationally recruited team to establish the guidelines for a “Genius Grant” in the research area of Women’s Health.
Mr. Dodd earned both a Bachelors of Science and Masters of Science degrees from Georgia State University, and he successfully completed the Advanced Management Program at Harvard Business School. In 2011, Mr. Dodd was recognized by Georgia State University, awarding him the Distinguished Alumni Achievement Award for his business achievements and civic contributions.
Dr. Michael E. Shannon M.A., M.Sc., M.D., President
Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.
He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces.
In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.
In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General’s office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.
Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.
Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.
Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.
Stephanie L. Sorensen, Chief Financial Officer
Stephanie L. Sorensen joined us as our Chief Financial Officer in October 2016. Ms. Sorensen also currently serves part-time as the Corporate Controller for Q Therapeutics, Inc. and Elute, Inc. both in Salt Lake City, Utah. Q Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing human cell-based therapies that can be sold as “off-the-shelf” pharmaceuticals intended to treat neurodegenerative diseases of the brain and spinal cord. Elute, Inc. is a start-up privately held company developing and commercializing a new class of polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections. From October 2009 to August 2012, Ms. Sorensen was the Assistant Controller of World Heart Corporation, a publicly traded medical device company that had developed a ventricular heart valve for late stage heart failure patients as a bridge-to-transplant solution. WorldHeart was acquired by HeartWare International, Inc. in 2012. From November 2007 to October 2009, Ms. Sorensen was the Assistant Controller of Amedica Corporation, a medical device company that developed and sold ceramic spinal implants. Prior to Amedica, Ms. Sorensen held various operational and financial positions for both private and public companies in the pharmaceutical, telecommunications and software development industries.